netFormulary NHS
Milton Keynes Formulary
Milton Keynes University Hospital NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes Clinical Commissioning Group
Milton Keynes Community Health Services
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

 

NHS Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation B04/P/a

Contacting Milton Keynes Hospital

      
For Haematology and Oncology:

  • During hours: Macmillan Unit on 01908 243671; Internal Ext 5111 or 5112
  • Out of hours: Advanced Nurse Practitioner on bleep 1090    

Paediatric patients:

  • During hours: Paediatric Day Community Unit on 01908 242703; Internal Ext 2703      

Pharmacy:

  • Cancer and Aseptic Services Manager on bleep 1721
  • Aseptic Unit 01908 243952
  • On-call pharmacist via switchboard 01908 660033
Chapter Links...
 Details...
08.02.04  Expand sub section  Other immunomodulating drugs
Axicabtagene ciloleucel (YESCARTA®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Single dose intravenous infusion

 

 

 
Link  NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
   
Canakinumab (Ilaris®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Ilaris injection, powder for reconstitution, 150mg vial

 
   
Cemiplimab (Libtayo®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Vial

 
Link  NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
   
Daclizumab (Zinbryta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Zinbryta® Solution for injection 150mg/1mL in pre-filled syringe / in pre-filled pen

 

 
Link  Drug Safety Update : Daclizumab beta (Zinbryta▼): risk of immune-mediated encephalitis – some cases several months after stopping treatment (Sept 2018)
Link  MHRA- risk of severe liver injury
Link  MHRA: risk of encephalitis persists for 12 months after stopping
Link  MHRA: suspension of marketing authorisation
Link  NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
   
Dimethyl fumarate (Tecfidera®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Homecare

Tecfidera® Capsules 120mg, 240mg

 

 
Link  EMA advice re minimising risk of PML
Link  MHRA Drug Safety Update (April 2016)
Link  NICE TA320: Dimethyl fumarate for multiple sclerosis
Link  NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
   
Cytotoxic Drug Dinutuximab beta
(Qarziba®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Qarziba® 20mg/4.5mL concentrate for solution for infusion

 

 
Link  NICE TA538: Dinutuximab beta for treating neuroblastoma
   
Fingolimod
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Homecare

Gilenya® Capsules 500mcg

 

 
Link  All MHRA Drug Safety Update
Link  NICE TA254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
   
LenalidomideBlack Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Capsules 2.5mg, 5mg, 10mg, 15mg, 25mg

 
Link  MHRA Drug Safety Update (Dec 2014)
Link  NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Link  NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Link  NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Link  NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
Link  NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
   
NiraparibBlack Triangle (Zejula®)
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsules 100mg

 
Link  NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Link  NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
   
Nivolumab (Opdivo®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

10mg/mL concentrate for solution for infusion in vial

 
Link  MHRA Drug Safety Update (July 2017)
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462:Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Link  NICE TA490:Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Link  NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (not recommended)
Link  NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Link  NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Link  NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
Link  NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
   
Olaparib (Lynparza®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsules 50mg

Film-coated tablets 100mg and 150mg 

To be used in line with the NICE TA's (see links below).

NB: NICE TA 598 and NICE TA 693 indications and one indication in NICE TA 620 are funded via the Cancer Drugs Fund.

 

 
Link  NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Link  NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Link  NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Link  NICE TA693: Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer
   
Pomalidomide (Imnovid®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Imnovid® Capsules 1mg, 2mg, 3mg, 4mg

 

 
Link  MHRA Drug Safety Update (May 2016)
Link  NICE New Medicine Evidence Summary 32: pomalidomide
Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
   
Rucaparib (Rubraca®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Tablets 300mg

 
Link  NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
   
Teriflunomide (Aubagio®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Homecare

Aubagio® 14mg tablets

 

 
Link  NICE TA 303: Teriflunomide for relapsing remitting MS
   
Thalidomide (Celgene®)
(haematology)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Capsules 50mg

Notes:


Original pack prescribing / dispensing only; Patient, prescriber, and supplying
pharmacy must comply with a pregnancy prevention programme. Every
prescription must be accompanied by a complete Prescription Authorisation
Form

Thalidomide: reduced starting dose in patients older than age 75 years (Last
updated December 2015)

Thalidomide in combination with an alkylating agent and a corticosteroid is
recommended as an option for the first-line treatment of multiple myeloma in
people for whom high-dose chemotherapy with stem cell transplantation is
considered inappropriate.

 
Link  MHRA Drug Safety Update (December 2015)
Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
   
Tisagenlecleucel  (Kymriah®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

Single-dose intravenous infusion

 

 
Link  NICE TA554:Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Link  NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
   
08.02.04  Expand sub section  Interferon Alfa
Interferon Alfa-2a (Roferon-A®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Interferon Alfa-2a (rbe), Roferon-A®
Injection, 3 million-unit in 0.5mL pre-filled syringe
Injection, 3 million-unit in 1mL vial
Injection, 4.5 million-unit in 0.5mL pre-filled syringe
Injection, 4.5 million-unit in 1mL vial
Injection, 6 million-unit in 0.5mL pre-filled syringe
Injection, 9 million-unit in 0.5mL pre-filled syringe

 

 
Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
   
Peginterferon Alfa
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Pegasys® Peginterferon alfa-2a Injection,
135 microgram pre-filled pen/syringe,
180 microgram pre-filled pen/syringe
ViraferonPeg® Peginterferon alfa-2b (rbe) Injection
50 microgram pre-filled pen,
80 microgram pre-filled pen,
120 microgram pre-filled pen,
150 microgram pre-filled pen

 

 
Link  NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Link  NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Link  NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
   
08.02.04  Expand sub section  Interferon beta
Interferon Beta-1a
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Homecare

Avonex® Injection, 30mcg (6 million-unit) powder and solvent for
solution (BIO-SET)
Avonex® Injection, 30mcg/0.5mL (6 million-unit) solution in Pre-filled syringe
Avonex® Injection, 30mcg/0.5mL (6 million-unit) solution in Pre-filled pen

 

 

 
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Interferon Beta-1a (Rebif®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Homecare

Rebif® Injection, 22mcg (6 million-unit) prefilled syringe or pen
Rebif® Injection, 44mcg (12 million-unit) prefilled syringe or pen
Rebif® Injection, 44mcg (12 million-units/mL) 1.5mL (66mcg, 18 million-unit) cartridge
Rebif® Injection, 88mcg (24 million-units/mL) 1.5mL (132mcg, 36 million-unit) cartridge

 
Link  Commissioning Policy - Multiple Sclerosis
Link  MHRA Drug Safety Update (Dec 2014)
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Interferon Beta-1b
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Betaferon® Injection, 300mcg (9.6 million-unit) powder for reconstitution, vial with diluent



 
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Interferon beta-1b (Extavia®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Extavia® Injection, 300mcg (9.6 million-unit), powder for reconstitution, vial
with diluent

 
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Peginterferon Beta-1a (Plegridy®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Plegridy® Injection, 63mcg/0.5mL solution in Pre-filled pen
Plegridy® Injection, 94mcg/0.5mL solution in Pre-filled pen
Plegridy® Injection, 125mcg/0.5mL solution in Pre-filled pen

 

Note: Use in line with NICE guidance (see link below) for treating relapsing-remitting multiple sclerosis although this service is not provided at Milton Keynes Hospital.

 
Link  NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
   
08.02.04  Expand sub section  Interferon gamma
08.02.04  Expand sub section  Aldesleukin to top
BCG bladder instillation
View adult BNF View SPC online View childrens BNF
Formulary
Red

Bacillus Calmette-Guérin
ImmuCyst® bladder instillation 81mg vial
OncoTICE® bladder instillation 12.5mg vial

 
   
08.02.04  Expand sub section  BCG bladder instillation
08.02.04  Expand sub section  Canakinumab
08.02.04  Expand sub section  Dimethyl fumarate
08.02.04  Expand sub section  Fingolimod
08.02.04  Expand sub section  Glatiramer acetate to top
Glatiramer Acetate
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Homecare

Copaxone® Injection, Glatiramer acetate 20mg/mL solution in Pre-filled
syringes
Copaxone® Injection, Glatiramer acetate 40mg/mL solution in Pre-filled
syringes

 

 
Link  Commissioning Policy - Multiple Sclerosis
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
   
08.02.04  Expand sub section  Histamine
08.02.04  Expand sub section  Lenalidomide, pomalidomide, and thalidomide
08.02.04  Expand sub section  Mifamurtide
Mifamurtide (Mepact®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Intravenous Infusion 4mg vial

 

 
Link  NICE TA235: Osteosarcoma - mifamurtide: guidance
   
08.02.04  Expand sub section  Natalizumab
Natalizumab (Tysabri®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tysabri® Concentrate for IV infusion 20mg/mL

 

 
Link  Commissioning Policy - Multiple Sclerosis
Link  MHRA Drug Safety Update (April 2016)
Link  NICE TA127: Multiple sclerosis - natalizumab
   
08.02.04  Expand sub section  Teriflunomide to top
 ....
 Non Formulary Items
Aldesleukin  (Proleukin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
BCG bladder instillation  (OncoTICE®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cediranib  (Recentin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cobimetinib  (Cotellic®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  NICE TA414:Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
 
Dinutuximab  (Unituxin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Fampridine

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NHS England national commissioning policy
 
Interferon Alfa  (Viraferon®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
Interferon Alfa-2b  (IntronA®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA75: Interferon Alfa - Chronic Hepatitis C
 
Interferon Beta  (Proleukin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
Peginterferon Alfa  (PegIntron®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
Peginterferon Alfa-2a  (Pegasys®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin
Link  NICE TA 300: Hepatitis C - peginterferon alfa
Link  NICE TA 96: Hepatitis B - peginterferon alfa
Link  NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Link  NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
 
Talimogene laherparepvac  (Imlygic®)

View adult BNF View SPC online View childrens BNF
Non Formulary
BlueTeq
Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
 
To delete this entry

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Routine prescribing within licensed indication  

Amber 1

Specialist recommendation followed by GP initiation and continuation  

Amber 2

Specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation   

Amber 3

Specialist initiation and stabilisation followed by GP continuation  

Amber SCG

Specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline  

Red

Hospital or specialist prescribing only  

Red Red

These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.  

netFormulary